Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKane Biotech Inc

Kane Biotech Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.035 CAD 0.00(0%)
Last update at 2026-11-03T17:10:00Z
VOLUME
8000
Market Cap
5.86M

Momentum Score

…

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate Acne Vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.03
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kane Biotech Inc is a Canadian biotechnology company developing and commercializing anti-biofilm technologies for human health, animal health and industrial applications. Its long-term growth could be supported by increasing recognition of biofilm-related problems and potential expansion of product sales and licensing across multiple end markets. Investors may find the company attractive for its focused technology platform and possible cross-sector commercialization opportunities.
The most important risks are limited commercial scale and ongoing losses that create financing and execution risk, plus regulatory approval and market-acceptance hurdles that could restrict revenue growth.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
-
Revenue TTM
0.57M
Revenue Per Share
0.00
Gross Profit TTM
-0.10M
Debt / Equity
-0.87
ROE
-596.80%
Net Debt
0.94M
ROCE
-4658.53%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -4.47M -4.56M -3.82M -4.85M -3.85M
Minority interest -0.07M 0.17M -0.07M 0.25M 2.56M
Net income 6.10M -5.03M -3.89M -4.60M -3.72M
Selling general administrative 3.08M 3.78M 3.72M 4.07M 3.43M
Gross profit 0.87M -0.13M 1.41M 0.57M 0.53M
Reconciled depreciation 0.22M 0.26M 0.26M 0.19M 0.08M
Ebit - -3.82M -3.00M -4.44M -3.73M
Ebitda - -3.58M -2.75M -4.25M -3.65M
Depreciation and amortization - 0.24M 0.26M 0.19M 0.08M
Operating income -3.92M -3.82M -3.36M -4.88M -4.22M
Other operating expenses - 3.97M 6.03M 6.49M 5.57M
Interest expense 0.55M 1.22M 0.82M 0.42M 0.12M
Tax provision -1.31M - - - -
Interest income 0.00M 0.07M 0.10M 0.12M 0.04M
Net interest income -0.54M -1.17M -0.72M -0.29M -0.08M
Income tax expense - 0.47M 1.14M 0.49M 0.45M
Total revenue 2.08M 0.15M 2.67M 1.61M 1.34M
Total operating expenses 6.00M 3.69M 4.78M 5.45M 4.75M
Cost of revenue 1.21M 0.28M 1.26M 1.04M 0.81M
Total other income expense net -0.01M -0.74M 0.26M 0.33M 0.46M
Net income from continuing ops -3.16M -4.50M -3.82M -4.85M -3.85M
Net income applicable to common shares - - -3.89M -4.60M -3.72M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.49M 5.68M 5.62M 6.13M 5.04M
Intangible assets 0.54M - 0.83M 0.83M 0.78M
Other current assets 0.21M 2.62M 0.17M 0.14M 0.14M
Total liab 4.12M 14.09M 9.76M 7.70M 3.96M
Total stockholder equity -1.63M -10.56M -6.52M -3.89M -1.49M
Other current liab 0.12M 2.67M 0.21M 1.58M 0.68M
Common stock - 23.69M 23.13M 22.16M 20.86M
Capital stock 24.40M - 23.13M 22.16M 20.86M
Retained earnings -34.42M -42.13M -37.10M -33.21M -28.61M
Other liab - - 0.84M 0.78M 0.35M
Other assets - - 0.44M 0.99M 1.36M
Cash 0.36M 0.75M 1.10M 1.15M 1.01M
Total current liabilities 2.41M 10.89M 6.34M 4.72M 2.92M
Current deferred revenue - 0.75M - - -
Net debt 0.94M 8.46M 4.66M 2.34M 1.16M
Short term debt - 7.04M - - -
Short long term debt 0.34M - 4.17M 2.38M 1.51M
Short long term debt total - 9.21M - - -
Other stockholder equity - 7.75M - 1.66M 1.84M
Property plant equipment - - 1.25M 1.44M 0.16M
Total current assets 1.03M 3.72M 3.10M 2.88M 2.74M
Net tangible assets - - -7.35M -4.71M -2.27M
Net receivables 0.01M 0.10M 1.06M 1.07M 1.12M
Long term debt 0.96M - 1.60M 1.12M 0.66M
Inventory 0.38M 0.25M 0.76M 0.52M 0.47M
Accounts payable 1.19M 0.44M 1.85M 0.63M 0.66M
Accumulated other comprehensive income - 0.14M - - -
Non currrent assets other - 0.89M - - -
Non current assets total 1.47M 1.96M 2.52M 3.25M 2.30M
Capital lease obligations 0.87M - 1.09M 1.22M 0.08M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 10.27M -0.12M -0.11M -0.37M -0.17M
Change to liabilities - - -0.09M 1.29M -0.02M
Total cashflows from investing activities - - -0.11M -0.37M -0.17M
Net borrowings -6.65M - 2.25M 1.25M 2.35M
Total cash from financing activities -7.00M 2.98M 3.10M 2.81M 4.28M
Change to operating activities - - -0.03M 0.01M -0.09M
Net income 6.10M -4.56M -3.82M -4.85M -3.85M
Change in cash -1.53M -0.36M -0.05M 0.15M 0.17M
Begin period cash flow 1.14M 1.10M 1.15M 1.01M 0.83M
End period cash flow 0.36M 0.75M 1.10M 1.15M 1.01M
Total cash from operating activities -4.11M -2.08M -3.04M -2.29M -3.94M
Issuance of capital stock 0.00M 0.42M 0.97M 0.00M 0.70M
Depreciation 0.22M 0.24M 0.26M 0.19M 0.08M
Other cashflows from investing activities - - -0.02M -0.02M -0.04M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory -0.13M -0.11M -0.24M -0.05M 0.12M
Change to account receivables - 0.01M -0.01M 0.04M -0.28M
Other cashflows from financing activities - 0.47M 2.66M 2.23M 3.60M
Change to netincome - - 0.78M 0.83M -0.03M
Capital expenditures 0.09M 0.05M 0.09M 0.35M 0.13M
Change in working capital -5.83M 0.59M -0.38M 1.29M -0.27M
Stock based compensation 0.71M 0.26M 0.28M 1.09M 0.46M
Other non cash items 4.20M 2.04M 0.43M -0.08M -0.41M
Free cash flow -4.20M -2.13M -3.13M -2.64M -4.07M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KNE
Kane Biotech Inc		 -
-%		 0.04 - - 10.19 104.38 12.55 -6.17
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
1.96%		 0.50 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 0.01
10.00%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 0.01
1.61%		 0.63 - - - 15.17 - -58.16

Profile*

Kane Biotech Inc

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. Its wound care product portfolio includes antimicrobial wound gel, antimicrobial wound gel spray, and antimicrobial wound rinse under revyve name, as well as antimicrobial surgical hydrogel under coactiv+ name. In addition, the company offers shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. Further, it engages in developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; revyve Antimicrobial Wound Rinse for use in acute and chronic wounds; DispersinB Hydrogel for use in surgical/acute wounds; and DispersinB Acne Cleanser for use in the treatment of mild to moderate Acne Vulgaris. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

290-100 Innovation Drive, Winnipeg, MB, Canada, R3T 6G2

204-453-1301

https://kanebiotech.com

Name Title Year Born
Mr. Marc Edwards Pres, CEO & Director NA
Mr. Ray Dupuis Chief Financial Officer NA
Mr. Kevin Cole Pres & CEO of STEM Animal Health Inc NA
Dr. Gregory S. Schultz Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board 1950
Lorne Gorber Investor Relations NA
Ms. Lori Christofalos VP of Quality & Compliance NA
Ms. Wendy Nachtigall Director of Marketing NA
Nicole Sendey Investor Relations Adviser NA
Mr. Mark Ahrens-Townsend Advisor NA
Mr. Marc Edwards President, CEO & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…